8 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Terminated 8 |
| Phase 2 | 1 | Terminated 1 |
Follow Fibromyalgia: new trials by email Literature Review of Fibromyalgia trials Research Report on Fibromyalgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia TNX-102 SL Tablet, 2.8 mg, Placebo SL Tablet - Fibromyalgia, Myofascial Pain Syndromes | Phase 3 | Terminated | Tonix Pharmaceuticals, Inc. | 51 | 2016-07-22 | 2025-02-25 |
| rTMS for the Treatment of Chronic Pain in GW1 Veterans rTMS, Sham device - Chronic Pain | Phase 3 | Terminated | VA Office of Research and Development | 17 | 2012-09-01 | 2017-04-11 |
| Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population Savella - Fibromyalgia | Phase 3 | Terminated | Banner Health | 20 | 2011-03-01 | 2011-08-17 |
| Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia Milnacipran, Placebo - Fibromyalgia | Phase 3 | Terminated | Forest Laboratories | 2 | 2008-11-01 | 2010-07-01 |
| Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia [S,S]-Reboxetine - Fibromyalgia | Phase 3 | Terminated | Pfizer | 390 | 2008-05-01 | 2019-12-17 |
| Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia [S,S]-reboxetine - Fibromyalgia | Phase 3 | Terminated | Pfizer | 500 | 2007-10-20 | 2019-12-13 |
| Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population PRIMA Device - Fibromyalgia, Pain | Phase 3 | Terminated | Fralex Therapeutics | 200 | 2007-03-01 | 2008-10-06 |
| Study Evaluating the Efficacy of DVS-233 in Fibromyalgia DVS-233 - Fibromyalgia | Phase 2 / Phase 3 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 1050 | 2006-08-01 | 2007-12-05 |
Pain (2) · Chronic Pain (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Myofascial Pain Syndromes (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Persian Gulf Syndrome (1) · Rheumatic Diseases (1)
Muscular Diseases (7) · Musculoskeletal Diseases (7) · Nervous System Diseases (7) · Neuromuscular Diseases (7) · Rheumatic Diseases (7) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Connective Tissue Diseases (1) · Occupational Diseases (1) · Pain (1) · Skin and Connective Tissue Diseases (1) · War-Related Injuries (1) · Wounds and Injuries (1)
Milnacipran (2) · O-methyl reboxetine (2)
Pfizer (2) · Banner Health (1) · Forest Laboratories (1) · Fralex Therapeutics (1) · Tonix Pharmaceuticals, Inc. (1) · VA Office of Research and Development (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (8) · Canada (3) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Netherlands (1) · South Africa (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Allan Spera (1) · John W Ashford, MD PhD (1) · Sandra Jacobson, MD (1)